US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.
FDA approves Ozempic for kidney disease treatment in diabetes patients
The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO). The medication is now approved to lessen the risk of kidney disease progression,
Medical News Today1d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
rheumatologyadvisor17h
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.
FiercePharma12d
Government watchdog recommends tweaks to FDA accelerated approval program
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Business Insider on MSN6d
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.